CA2949994A1 - Purified compositions of ivig and kh proteins for modulating lymphocytes and treating hepatitis b virus - Google Patents
Purified compositions of ivig and kh proteins for modulating lymphocytes and treating hepatitis b virus Download PDFInfo
- Publication number
- CA2949994A1 CA2949994A1 CA2949994A CA2949994A CA2949994A1 CA 2949994 A1 CA2949994 A1 CA 2949994A1 CA 2949994 A CA2949994 A CA 2949994A CA 2949994 A CA2949994 A CA 2949994A CA 2949994 A1 CA2949994 A1 CA 2949994A1
- Authority
- CA
- Canada
- Prior art keywords
- amino acid
- acid sequence
- protein
- sequence seq
- substantially pure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 216
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 216
- 239000000203 mixture Substances 0.000 title claims description 5
- 241000700721 Hepatitis B virus Species 0.000 title abstract description 4
- 210000004698 lymphocyte Anatomy 0.000 title description 19
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 186
- 210000005259 peripheral blood Anatomy 0.000 claims abstract description 61
- 239000011886 peripheral blood Substances 0.000 claims abstract description 61
- 210000003714 granulocyte Anatomy 0.000 claims abstract description 53
- 238000000034 method Methods 0.000 claims abstract description 52
- 210000002540 macrophage Anatomy 0.000 claims abstract description 39
- 210000003719 b-lymphocyte Anatomy 0.000 claims abstract description 35
- 210000002381 plasma Anatomy 0.000 claims abstract description 34
- 230000001105 regulatory effect Effects 0.000 claims abstract description 20
- 238000004519 manufacturing process Methods 0.000 claims abstract description 19
- 101001018097 Homo sapiens L-selectin Proteins 0.000 claims abstract description 9
- 102100033467 L-selectin Human genes 0.000 claims abstract description 9
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims abstract 4
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims abstract 4
- 241000282414 Homo sapiens Species 0.000 claims description 496
- 210000000952 spleen Anatomy 0.000 claims description 84
- 230000000694 effects Effects 0.000 claims description 51
- 239000000047 product Substances 0.000 claims description 39
- 208000002672 hepatitis B Diseases 0.000 claims description 26
- 108060003951 Immunoglobulin Proteins 0.000 claims description 20
- 102000018358 immunoglobulin Human genes 0.000 claims description 20
- 229940060415 hepatitis b immune globulin Drugs 0.000 claims description 9
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 claims description 5
- 239000000427 antigen Substances 0.000 claims description 5
- 108091007433 antigens Proteins 0.000 claims description 5
- 102000036639 antigens Human genes 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 239000012467 final product Substances 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 238000000108 ultra-filtration Methods 0.000 claims description 3
- 238000011146 sterile filtration Methods 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 87
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 4
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims 4
- 239000002031 ethanolic fraction Substances 0.000 claims 4
- 239000000706 filtrate Substances 0.000 claims 4
- 238000007865 diluting Methods 0.000 claims 2
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 108
- 208000015181 infectious disease Diseases 0.000 abstract description 27
- 201000010099 disease Diseases 0.000 abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 10
- 210000002865 immune cell Anatomy 0.000 abstract description 8
- 210000000056 organ Anatomy 0.000 abstract description 4
- 210000001165 lymph node Anatomy 0.000 description 76
- 230000027455 binding Effects 0.000 description 67
- 230000001225 therapeutic effect Effects 0.000 description 67
- 210000004027 cell Anatomy 0.000 description 64
- 229940039715 human prothrombin Drugs 0.000 description 64
- 230000001086 cytosolic effect Effects 0.000 description 53
- 108010088751 Albumins Proteins 0.000 description 46
- 102000009027 Albumins Human genes 0.000 description 46
- 230000000069 prophylactic effect Effects 0.000 description 45
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 44
- 230000003828 downregulation Effects 0.000 description 44
- 229940106780 human fibrinogen Drugs 0.000 description 40
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 36
- 210000003289 regulatory T cell Anatomy 0.000 description 33
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 30
- 230000003827 upregulation Effects 0.000 description 29
- 102000003886 Glycoproteins Human genes 0.000 description 26
- 108090000288 Glycoproteins Proteins 0.000 description 26
- 230000008569 process Effects 0.000 description 23
- 210000004443 dendritic cell Anatomy 0.000 description 21
- 210000004165 myocardium Anatomy 0.000 description 19
- 210000001616 monocyte Anatomy 0.000 description 18
- 208000035473 Communicable disease Diseases 0.000 description 16
- 238000011321 prophylaxis Methods 0.000 description 16
- 238000012353 t test Methods 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 15
- 235000012000 cholesterol Nutrition 0.000 description 15
- 239000002245 particle Substances 0.000 description 15
- 230000003247 decreasing effect Effects 0.000 description 14
- 210000003071 memory t lymphocyte Anatomy 0.000 description 14
- 230000004060 metabolic process Effects 0.000 description 14
- 230000021953 cytokinesis Effects 0.000 description 13
- 230000033228 biological regulation Effects 0.000 description 12
- 210000000182 cd11c+cd123- dc Anatomy 0.000 description 12
- 230000001413 cellular effect Effects 0.000 description 12
- 102000005962 receptors Human genes 0.000 description 12
- 108020003175 receptors Proteins 0.000 description 12
- 210000004544 dc2 Anatomy 0.000 description 11
- 230000019491 signal transduction Effects 0.000 description 11
- 210000001723 extracellular space Anatomy 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- 230000017734 multicellular organismal process Effects 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 9
- 230000003436 cytoskeletal effect Effects 0.000 description 9
- 230000003834 intracellular effect Effects 0.000 description 9
- 210000005061 intracellular organelle Anatomy 0.000 description 9
- 101150079748 MCM8 gene Proteins 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 210000000170 cell membrane Anatomy 0.000 description 8
- 108091060290 Chromatid Proteins 0.000 description 7
- 101100407318 Xenopus laevis pds5a-a gene Proteins 0.000 description 7
- 210000004756 chromatid Anatomy 0.000 description 7
- 101150109441 pds5 gene Proteins 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 108010010234 HDL Lipoproteins Proteins 0.000 description 6
- 102000015779 HDL Lipoproteins Human genes 0.000 description 6
- 102000004895 Lipoproteins Human genes 0.000 description 6
- 108090001030 Lipoproteins Proteins 0.000 description 6
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000033077 cellular process Effects 0.000 description 6
- 210000001163 endosome Anatomy 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 210000003632 microfilament Anatomy 0.000 description 6
- 210000003463 organelle Anatomy 0.000 description 6
- 150000003904 phospholipids Chemical class 0.000 description 6
- 230000033210 regulation of biological quality Effects 0.000 description 6
- 230000025969 response to chemical stimulus Effects 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 101000713288 Homo sapiens Solute carrier family 22 member 5 Proteins 0.000 description 5
- 101000631826 Homo sapiens Stearoyl-CoA desaturase Proteins 0.000 description 5
- 230000004075 alteration Effects 0.000 description 5
- 230000023555 blood coagulation Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 210000003563 lymphoid tissue Anatomy 0.000 description 5
- 230000021592 metal ion homeostasis Effects 0.000 description 5
- 230000003938 response to stress Effects 0.000 description 5
- 230000026676 system process Effects 0.000 description 5
- 230000032258 transport Effects 0.000 description 5
- 210000003956 transport vesicle Anatomy 0.000 description 5
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 4
- 238000011725 BALB/c mouse Methods 0.000 description 4
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 4
- 102100022297 Integrin alpha-X Human genes 0.000 description 4
- 108060004795 Methyltransferase Proteins 0.000 description 4
- 101150011967 Mthfsd gene Proteins 0.000 description 4
- 108090000190 Thrombin Proteins 0.000 description 4
- 102000004338 Transferrin Human genes 0.000 description 4
- 108090000901 Transferrin Proteins 0.000 description 4
- 101100537444 Xenopus laevis tmem267 gene Proteins 0.000 description 4
- 239000012190 activator Substances 0.000 description 4
- 230000001851 biosynthetic effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229910001424 calcium ion Inorganic materials 0.000 description 4
- 230000012292 cell migration Effects 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 238000010212 intracellular staining Methods 0.000 description 4
- 229920002521 macromolecule Polymers 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 229960004452 methionine Drugs 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 230000010118 platelet activation Effects 0.000 description 4
- 238000007634 remodeling Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 229960004072 thrombin Drugs 0.000 description 4
- 230000025366 tissue development Effects 0.000 description 4
- 230000026683 transduction Effects 0.000 description 4
- 238000010361 transduction Methods 0.000 description 4
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 3
- 102000057234 Acyl transferases Human genes 0.000 description 3
- 108700016155 Acyl transferases Proteins 0.000 description 3
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 3
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 3
- 102000005666 Apolipoprotein A-I Human genes 0.000 description 3
- 108010059886 Apolipoprotein A-I Proteins 0.000 description 3
- 102100032912 CD44 antigen Human genes 0.000 description 3
- 108091007403 Cholesterol transporters Proteins 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 3
- 108091006109 GTPases Proteins 0.000 description 3
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 3
- 101000961156 Homo sapiens Immunoglobulin heavy constant gamma 1 Proteins 0.000 description 3
- 102000004157 Hydrolases Human genes 0.000 description 3
- 108090000604 Hydrolases Proteins 0.000 description 3
- 102100039345 Immunoglobulin heavy constant gamma 1 Human genes 0.000 description 3
- 102000003777 Interleukin-1 beta Human genes 0.000 description 3
- 108090000193 Interleukin-1 beta Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 3
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 3
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000000748 cardiovascular system Anatomy 0.000 description 3
- 102000013515 cdc42 GTP-Binding Protein Human genes 0.000 description 3
- 108010051348 cdc42 GTP-Binding Protein Proteins 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 230000019522 cellular metabolic process Effects 0.000 description 3
- 230000031154 cholesterol homeostasis Effects 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 230000032050 esterification Effects 0.000 description 3
- 238000005886 esterification reaction Methods 0.000 description 3
- 230000015862 eukaryotic cell surface binding Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000020764 fibrinolysis Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000012667 heterotypic cell-cell adhesion Effects 0.000 description 3
- 230000008676 import Effects 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 230000015788 innate immune response Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000008604 lipoprotein metabolism Effects 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 210000003470 mitochondria Anatomy 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000033087 muscle system process Effects 0.000 description 3
- 210000003365 myofibril Anatomy 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 230000005305 organ development Effects 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 3
- 230000012006 phospholipid homeostasis Effects 0.000 description 3
- 230000019525 primary metabolic process Effects 0.000 description 3
- 230000006318 protein oxidation Effects 0.000 description 3
- 230000029983 protein stabilization Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000012121 regulation of immune response Effects 0.000 description 3
- 230000004141 reverse cholesterol transport Effects 0.000 description 3
- 210000002235 sarcomere Anatomy 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 102000040811 transporter activity Human genes 0.000 description 3
- 230000008601 triglyceride homeostasis Effects 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 208000030090 Acute Disease Diseases 0.000 description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
- 102000053028 CD36 Antigens Human genes 0.000 description 2
- 108010045374 CD36 Antigens Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 230000004543 DNA replication Effects 0.000 description 2
- 102100021238 Dynamin-2 Human genes 0.000 description 2
- 108010059378 Endopeptidases Proteins 0.000 description 2
- 102000005593 Endopeptidases Human genes 0.000 description 2
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
- 101000817607 Homo sapiens Dynamin-2 Proteins 0.000 description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 2
- 208000024556 Mendelian disease Diseases 0.000 description 2
- 108010006519 Molecular Chaperones Proteins 0.000 description 2
- 108010085220 Multiprotein Complexes Proteins 0.000 description 2
- 102000007474 Multiprotein Complexes Human genes 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108060008487 Myosin Proteins 0.000 description 2
- 102000003505 Myosin Human genes 0.000 description 2
- 102000015439 Phospholipases Human genes 0.000 description 2
- 108010064785 Phospholipases Proteins 0.000 description 2
- 101800000460 Protein TF Proteins 0.000 description 2
- 108020005202 Viral DNA Proteins 0.000 description 2
- 208000037919 acquired disease Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000004721 adaptive immunity Effects 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 210000001130 astrocyte Anatomy 0.000 description 2
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 210000004292 cytoskeleton Anatomy 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000000521 hyperimmunizing effect Effects 0.000 description 2
- 230000007813 immunodeficiency Effects 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 230000023837 negative regulation of proteolysis Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 230000011363 regulation of cellular process Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 230000033772 system development Effects 0.000 description 2
- 239000012581 transferrin Substances 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- VVIAGPKUTFNRDU-STQMWFEESA-N (6S)-5-formyltetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1C=O)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-STQMWFEESA-N 0.000 description 1
- WUUGFSXJNOTRMR-IOSLPCCCSA-N 5'-S-methyl-5'-thioadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CSC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 WUUGFSXJNOTRMR-IOSLPCCCSA-N 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 108010043137 Actomyosin Proteins 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 239000012114 Alexa Fluor 647 Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101100205030 Caenorhabditis elegans hars-1 gene Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 102100033482 Enolase-phosphatase E1 Human genes 0.000 description 1
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000850450 Homo sapiens Enolase-phosphatase E1 Proteins 0.000 description 1
- 101000839684 Homo sapiens Immunoglobulin heavy variable 4-31 Proteins 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 102100028310 Immunoglobulin heavy variable 4-31 Human genes 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 229930195722 L-methionine Natural products 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 101001065556 Mus musculus Lymphocyte antigen 6G Proteins 0.000 description 1
- 101100082091 Mus musculus Pacrgl gene Proteins 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 102100038843 Neuropeptides B/W receptor type 2 Human genes 0.000 description 1
- 101710150355 Neuropeptides B/W receptor type 2 Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108010058514 Phosphate-Binding Proteins Proteins 0.000 description 1
- 102000006335 Phosphate-Binding Proteins Human genes 0.000 description 1
- 101710177166 Phosphoprotein Proteins 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 101710134436 Putative uncharacterized protein Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 108090000054 Syndecan-2 Proteins 0.000 description 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000011230 antibody-based therapy Methods 0.000 description 1
- 230000027645 antigenic variation Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004970 cd4 cell Anatomy 0.000 description 1
- 230000034196 cell chemotaxis Effects 0.000 description 1
- 230000023402 cell communication Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000015861 cell surface binding Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 230000004613 cellular response to starvation Effects 0.000 description 1
- 230000012018 cellular response to stimulus Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000005219 defense response to fungus Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000441 effect on granulocytes Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000003878 glomerular mesangial cell Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229940036107 hepatitis b immunoglobulin Drugs 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000016506 interphase of mitotic cell cycle Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000004576 lipid-binding Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000016557 multi-organism process Effects 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000008212 organismal development Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
- 229960001327 pyridoxal phosphate Drugs 0.000 description 1
- 230000020964 regulation of blood coagulation Effects 0.000 description 1
- 230000031931 regulation of body fluid levels Effects 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 230000004005 regulation of localization Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000007109 response to nutrient levels Effects 0.000 description 1
- 230000021670 response to stimulus Effects 0.000 description 1
- 230000022120 response to tumor cell Effects 0.000 description 1
- 230000008593 response to virus Effects 0.000 description 1
- 230000008399 response to wounding Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 108010038196 saccharide-binding proteins Proteins 0.000 description 1
- 238000011519 second-line treatment Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 102000030938 small GTPase Human genes 0.000 description 1
- 108060007624 small GTPase Proteins 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000003518 stress fiber Anatomy 0.000 description 1
- 210000003699 striated muscle Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000024033 toxin binding Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462003664P | 2014-05-28 | 2014-05-28 | |
| US62/003,664 | 2014-05-28 | ||
| PCT/US2015/032807 WO2015184050A1 (en) | 2014-05-28 | 2015-05-28 | Purified compositions of ivig and kh proteins for modulating lymphocytes and treating hepatitis b virus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2949994A1 true CA2949994A1 (en) | 2015-12-03 |
Family
ID=54699755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2949994A Pending CA2949994A1 (en) | 2014-05-28 | 2015-05-28 | Purified compositions of ivig and kh proteins for modulating lymphocytes and treating hepatitis b virus |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP3148574B1 (enExample) |
| JP (1) | JP2017525752A (enExample) |
| CN (1) | CN107106664A (enExample) |
| AU (1) | AU2015266997A1 (enExample) |
| BR (1) | BR112016027818A2 (enExample) |
| CA (1) | CA2949994A1 (enExample) |
| ES (1) | ES2878043T3 (enExample) |
| MX (1) | MX2016015574A (enExample) |
| RU (1) | RU2016151761A (enExample) |
| WO (1) | WO2015184050A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2878043T3 (es) | 2014-05-28 | 2021-11-18 | Rare Antibody Antigen Supply Inc | Composiciones purificadas de proteínas IVIG y KH para la modulación de los linfocitos y el tratamiento del virus de la hepatitis B |
| CN107921079A (zh) * | 2015-04-02 | 2018-04-17 | K·黄 | 由组分iii制造静脉注射免疫球蛋白的方法 |
| US10583179B2 (en) * | 2015-04-02 | 2020-03-10 | Kieu Hoang | Method of manufacturing and purifying prothrombin complex concentrate from Fraction III for intravenous injection and a method of curing and preventing Hemophilia A with inhibitors or Hemophilia B in patients infected with HIV-1 and HIV-2 |
| CN118903378A (zh) * | 2024-03-19 | 2024-11-08 | 北京达尔文细胞生物科技有限公司 | 一种蛋白聚合物在治疗渐冻症中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3825429C2 (de) * | 1988-07-27 | 1994-02-10 | Biotest Pharma Gmbh | Verfahren zur Herstellung eines intravenös verabreichbaren polyklonalen Immunglobulin-Präparates mit hohem IgM-Gehalt |
| US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| GB0315248D0 (en) * | 2003-06-30 | 2003-08-06 | Hoffmann La Roche | HCV regulated protein expression |
| TWI489994B (zh) * | 2008-03-17 | 2015-07-01 | Baxter Healthcare Sa | 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法 |
| CA2639003A1 (en) * | 2008-08-20 | 2010-02-20 | Canadian Blood Services | Inhibition of fc.gamma.r-mediated phagocytosis with reduced immunoglobulin preparations |
| JP5969458B2 (ja) * | 2010-04-09 | 2016-08-17 | アルブミディクス アクティーゼルスカブ | アルブミン誘導体及び変異体 |
| SG185483A1 (en) * | 2010-05-14 | 2012-12-28 | Univ Colorado Regents | Improved complement receptor 2 (cr2) targeting groups |
| TW201335181A (zh) * | 2012-01-31 | 2013-09-01 | Kieu Hoang | ５５種新發現的蛋白質之序列及其應用 |
| ES2878043T3 (es) | 2014-05-28 | 2021-11-18 | Rare Antibody Antigen Supply Inc | Composiciones purificadas de proteínas IVIG y KH para la modulación de los linfocitos y el tratamiento del virus de la hepatitis B |
-
2015
- 2015-05-28 ES ES15799654T patent/ES2878043T3/es active Active
- 2015-05-28 EP EP15799654.7A patent/EP3148574B1/en not_active Revoked
- 2015-05-28 CN CN201580041532.2A patent/CN107106664A/zh active Pending
- 2015-05-28 MX MX2016015574A patent/MX2016015574A/es unknown
- 2015-05-28 RU RU2016151761A patent/RU2016151761A/ru not_active Application Discontinuation
- 2015-05-28 BR BR112016027818A patent/BR112016027818A2/pt not_active Application Discontinuation
- 2015-05-28 JP JP2017515008A patent/JP2017525752A/ja active Pending
- 2015-05-28 AU AU2015266997A patent/AU2015266997A1/en not_active Abandoned
- 2015-05-28 WO PCT/US2015/032807 patent/WO2015184050A1/en not_active Ceased
- 2015-05-28 CA CA2949994A patent/CA2949994A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2878043T3 (es) | 2021-11-18 |
| RU2016151761A3 (enExample) | 2018-12-26 |
| JP2017525752A (ja) | 2017-09-07 |
| WO2015184050A1 (en) | 2015-12-03 |
| EP3148574B1 (en) | 2021-04-14 |
| CN107106664A (zh) | 2017-08-29 |
| EP3148574A4 (en) | 2017-04-05 |
| BR112016027818A2 (pt) | 2017-10-24 |
| EP3148574A1 (en) | 2017-04-05 |
| RU2016151761A (ru) | 2018-07-03 |
| MX2016015574A (es) | 2018-05-28 |
| AU2015266997A1 (en) | 2016-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2735139C2 (ru) | Полученные из лизата тромбоцитов человека внеклеточные везикулы для применения в медицине | |
| EP3134120B1 (en) | Compositions and methods for treating cytokine-related disorders | |
| CN105101978A (zh) | Nk细胞强化型血液制剂的制造方法 | |
| JP5847518B2 (ja) | Ｎｋ細胞強化型血液製剤の製造方法 | |
| US20190328792A1 (en) | Mesenchymal stem cell-derived extracellular vesicles and their medical use | |
| WO2012099093A1 (ja) | Nk細胞強化型血液製剤の製造方法 | |
| EP3148574B1 (en) | Purified compositions of ivig and kh proteins for modulating lymphocytes and treating hepatitis b virus | |
| CN106754723B (zh) | 一种具有抗肿瘤功能的免疫细胞及其应用 | |
| JP2022541293A (ja) | がん細胞療法用のｐ２１発現単球 | |
| CN111286488B (zh) | 一种自然杀伤细胞体外培养方法 | |
| CN115120713A (zh) | 氢氧化铝-CpG寡核苷酸-多肽复合佐剂、疫苗及制备方法和用途 | |
| JP2017520582A (ja) | 関節リウマチ治療のための間葉系間質細胞 | |
| JP4275680B2 (ja) | リンパ球の活性・増殖に係る培養方法 | |
| NZ537382A (en) | Extracorporeal photopheresis in combination with anti-TNF treatment | |
| JP5386083B2 (ja) | 自己免疫疾患および変性疾患を治療する方法 | |
| US20180021376A1 (en) | Naming of KH1 through KH55 good healthy cells synthesizes the KH1 through KH55 proteins | |
| CN103013906A (zh) | 一种生物膜及其制备方法和应用 | |
| JP7762964B2 (ja) | カクテル樹状細胞ワクチンの製造方法 | |
| CN117986351B (zh) | 一种ra自身抗原表位多肽及其制备的抗原特异性t细胞疫苗、制备方法和应用 | |
| US20240200030A1 (en) | Tumor proximal cell collection | |
| Crum | Matrix-bound nanovesicles as an immunomodulatory therapy for rheumatoid arthritis. | |
| Gkanatsiou | Identification of immunosuppressive mechanisms in Glioblastoma Mulltiforme brain tumours | |
| CN119923275A (zh) | CD158d分子、其中和抗体，及应用 | |
| CN109402056A (zh) | 靶向kif20a阳性胰腺癌双特异性抗体nk细胞及制备方法和应用 | |
| CN114667152A (zh) | 免疫活性改善用组合物及其方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20200519 |
|
| EEER | Examination request |
Effective date: 20200519 |
|
| EEER | Examination request |
Effective date: 20200519 |
|
| EEER | Examination request |
Effective date: 20200519 |
|
| EEER | Examination request |
Effective date: 20200519 |
|
| EEER | Examination request |
Effective date: 20200519 |